Successful treatment of relapsed CML after cord blood transplantation with donor leukocyte infusion IL-2 and IFNα

Bone Marrow Transplantation

Volumn 25, Issue 2, 2000, Pages 219-222

  Laws, H J ^a   Nurnberger W ^a   Korholz D ^a   Kogler G ^a   Fischer, J ^a   Niehues, T ^a   Wernet, P ^a   Gobel U ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

CML; Cord blood transplantation; Donor lymphocyte infusion; Relapse

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; INTERLEUKIN 2;

ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CASE REPORT; CELL MATURATION; CELL TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LEUKAPHERESIS; LEUKEMIA REMISSION; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; THROMBOCYTE TRANSFUSION; UMBILICAL CORD BLOOD;

EID: 0343049044     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702103     Document Type: Article

References (27)

1. Grier H, Civin C. Myeloid leukemias, myelodysplasia, and myeloproliferative diseases in children. In: Nathan D, Orkin S (eds). Nathan and Oski's Hematology of Infancy and Childhood, 5th edn. WB Saunders: Philadelphia, 1998, pp 1286-1321.
2. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954-1956.
3. Goldman JM, Szydlo R, Horowitz, MM et al. Choice of pre-transplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993; 82; 2235-2238.
4. Rubinstein P, Carrier C, Scaradavoa A et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. New Engl J Med 1998; 339: 1565-1577.
5. Gluckman E, Rocha V, Boyer-Chammard A et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. New Engl J Med 1997; 337: 373-381.
6. Wagner JE, Kernan NA, Steinbuch M et al. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet 1995; 346: 214-219.
7. Kolb HJ, Schattenberg A, Goldman JM et al. Gratt-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
8. Collins R Jr, Shpilberg O, Drohyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation (see comments). J Clin Oncol 1997; 15: 433-444.
9. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
10. Kapelushnik J, Nagler A, Or R et al. Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 18: 1153-1156.
11. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
12. Locatelli F, Comoli P, Giorgiani G et al. Infusion of donor-derived peripheral blood leukocytes after transplantation of cord blood progenitor cells can increase the graft-versus-leukaemia effect. Leukemia 1997; 11: 729-731.
13. Bogdanic V, Aurer I, Labar B et al. Treatment of chronic myeloid leukemia in relapse after umbilical cord blood transplantation (letter). Haematologica 1998; 83: 575-576.
14. Kogler G, Callejas J, Sorg RV et al. The effect of different thawing methods, growth factor combinations and media on the ex vivo expansion of umbilical cord blood primitive and committed progenitors. Bone Marrow Transplant 1998; 21: 233-241.
15. Kogler G, Hernandez, A, Heyll A et al. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse. Cancer Detect Prev 1996; 20: 601-609.
16. Dilloo D, Laws H-J, Hanenberg H et al. Induction of two distinct NK-cell populations, activated T-cells and antineoplastic cytokines by IL2 therapy in children with solid tumors. Exp Hematol 1994; 22: 1081-1088.
17. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
18. Kurtzberg J, Laughlin M, Graham ML et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. New Engl J Med 1996; 335: 157-166.
19. Chalmers IM, Janossy G, Contreras M, Navarrete C. Intracellular cytokine profile of cord and adult blood lymphocytes. Blood 1998; 92: 11-18.
20. Barrett AJ, Locatelli F, Treleaven JG et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br J Haematol 1991; 79: 567-574.
21. Chiang KY, Weisdorf DJ, Davies SM et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant 1996; 17: 39-42.
22. Talpaz M, Kantarjian H, Kurzrock R et al. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 1991; 114: 532-538.
23. Arcese W, Aversa F, Bandini G et al. Clinical use of allogeneic hematopoietic stem cells from sources other than bone marrow. Haematologica 1998; 83: 159-182.
24. Dilloo D, Hanenberg H, Lion T, Burdach S. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein. Leukemia 1995; 9: 419-424.
25. Soiffer RJ, Murray C, Cochran K et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant lnterleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1990; 79: 517-526.
26. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995: 86: 1261-1268.
27. Lin F, Kirkland MA, van Rhee FV et al. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 1996; 18: 1147-1152.